Eli Lilly gets drug regulator nod for Alzheimer's disease medication

Eli Lilly and Company (India) on Tuesday said it has received approval from national drug regulator CDSCO for a drug to treat Alzheimer's disease. The company has received marketing authorisation from the Central Drugs Standard Control Organization (CDSCO) for donanemab (350 mg/20 mL), administered every four weeks via intravenous infusion, for the treatment of Alzheimer's disease in adults with early symptomatic stages. This includes individuals with mild cognitive impairment and those in the mild dementia ...